Mutations in the p53 gene in primary human breast cancers.

Richard J. Osborne(National Institutes of Health), G Merlo(National Institutes of Health), Tetsuya Mitsudomi(National Institutes of Health), Tiziana Venesio(National Institutes of Health), Daniel S. Liscia, A. P. M. Cappa(Center for Neuro-Oncology), Itsuo Chiba(National Institutes of Health), Takashi Takahashi(National Institutes of Health), Marion M. Nau(National Institutes of Health), Robert Callahan(National Institutes of Health)
PubMed
November 15, 1991
Cited by 164

Abstract

Twenty-six primary breast tumors were examined for mutations in the p53 tumor suppressor gene by an RNase protection assay and nucleotide sequence analysis of PCR-amplified p53 complementary DNAs. Each method detected p53 mutations in the same three tumors (12%). One tumor contained two mutations in the same allele. Single strand conformation polymorphism analysis of genomic DNA and complementary DNA proved more sensitive in the detection of mutations. Combining this technique with the other two a total of 12 mutations in the p53 gene were demonstrated in 11 tumors (46%), and a polymorphism at codon 213 was detected in another tumor. Loss of heterozygosity on chromosome 17p was detected by Southern blot analysis in 30% of the tumor DNAs. Not all of the tumors containing a point mutation in p53 also had loss of heterozygosity of the remaining allele, suggesting that loss of heterozygosity may represent a later event.


Related Papers

No related papers found

Powered by citation graph analysis